Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Buy
67
KALV Quote, Financials, Valuation and Earnings
Last price:
$16.41
Seasonality move
:
6.97%
Day range:
$14.30 - $16.80
52-week range:
$7.30 - $17.28
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
56.89x
P/B ratio:
48.77x
Volume:
2.8M
Avg. volume:
1.5M
1-year change:
73.36%
Market cap:
$829M
Revenue:
--
EPS (TTM):
-$4.01
Analysts' Opinion
-
Consensus RatingKalVista Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $31.00, KalVista Pharmaceuticals, Inc. has an estimated upside of 89.02% from its current price of $16.40.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $22.00 representing -34.15% downside risk from its current price of $16.40.
Fair Value
-
According to the consensus of 7 analysts, KalVista Pharmaceuticals, Inc. has 89.02% upside to fair value with a price target of $31.00 per share.
KALV vs. S&P 500
-
Over the past 5 trading days, KalVista Pharmaceuticals, Inc. has overperformed the S&P 500 by 16.18% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
KalVista Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
KalVista Pharmaceuticals, Inc. revenues have been falling on a year-over-year basis for 4 quarters in a row. In the most recent quarter KalVista Pharmaceuticals, Inc. reported revenues of $13.7M.
Earnings Growth
-
KalVista Pharmaceuticals, Inc. earnings have been falling on a year-over-year basis for 8 quarters in a row. In the most recent quarter KalVista Pharmaceuticals, Inc. reported earnings per share of -$0.92.
Enterprise value:
802.4M
EV / Invested capital:
2.68x
Price / LTM sales:
56.89x
EV / EBIT:
--
EV / Revenue:
53.07x
PEG ratio (5yr expected):
-0.40x
EV / Free cash flow:
-4.77x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$12.6M
Return On Assets:
-84.6%
Net Income Margin (TTM):
-1391.14%
Return On Equity:
-243.25%
Return On Invested Capital:
-97.51%
Operating Margin:
-336.33%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | $15.1M | -- | $13.7M | |
| Gross Profit | -- | -- | $12.6M | -- | $12.5M | |
| Operating Income | -- | -- | -$203M | -- | -$46.1M | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -$4.01 | -- | -$0.92 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | -- | -- | $325.2M | |
| Total Assets | -- | -- | -- | -- | $339.9M | |
| Current Liabilities | -- | -- | -- | -- | $45.1M | |
| Total Liabilities | -- | -- | -- | -- | $322.9M | |
| Total Equity | -- | -- | -- | -- | $17M | |
| Total Debt | -- | -- | -- | -- | $281.2M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-07-31 | 2024-07-31 | 2025-07-31 | 2024-07-31 | 2025-07-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$79.2M | -$102.7M | -$167.2M | -$40.2M | -$54.5M | |
| Cash From Investing | $31M | -$67.2M | $75.1M | $37.2M | $21.3M | |
| Cash From Financing | $58.2M | $153.5M | $179.9M | $3M | $23.2M | |
| Free Cash Flow | -$79.5M | -$103.2M | -$168.4M | -$40.2M | -$54.8M | |
KALV
Sector
Market Cap
$829M
$28.4M
Price % of 52-Week High
94.91%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-18.67%
-1.32%
1-Year Price Total Return
73.36%
-22.19%
Beta (5-Year)
-0.135
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$14.21
200-day SMA
Buy
Level
$12.65
Bollinger Bands (100)
Buy
Level
11.53 - 14.53
Chaikin Money Flow
Sell
Level
-21.5M
20-day SMA
Buy
Level
$13.34
Relative Strength Index (RSI14)
Buy
Level
71.46
ADX Line
Buy
Level
29.17
Williams %R
Sell
Level
-10.0503
50-day SMA
Buy
Level
$12.18
MACD (12, 26)
Buy
Level
0.80
25-day Aroon Oscillator
Buy
Level
72
On Balance Volume
Neutral
Level
36.2M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-2.6)
Sell
CA Score
(Annual)
Level (-3.4892)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
Sell
Ohlson Score
Level (4.6325)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Sell
Fundamental Score
Level (1)
Revenue Forecast
Earnings per Share Forecast
Company Profile
KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet need. Its product candidates are inhibitors of plasma kallikrein being developed for two indications: Sebetralstat for HAE and Factor XIIa. The company was founded by T. Andrew Crockett, Edward P. Feener, and Lloyd Paul Aiello on March 26, 2004 and is headquartered in Framingham, MA.
Stock Forecast FAQ
In the current month, KALV has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The KALV average analyst price target in the past 3 months is $31.00.
-
Where Will KalVista Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that KalVista Pharmaceuticals, Inc. share price will rise to $31.00 per share over the next 12 months.
-
What Do Analysts Say About KalVista Pharmaceuticals, Inc.?
Analysts are divided on their view about KalVista Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that KalVista Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $22.00.
-
What Is KalVista Pharmaceuticals, Inc.'s Price Target?
The price target for KalVista Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $31.00 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is KALV A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for KalVista Pharmaceuticals, Inc. is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of KALV?
You can purchase shares of KalVista Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase KalVista Pharmaceuticals, Inc. shares.
-
What Is The KalVista Pharmaceuticals, Inc. Share Price Today?
KalVista Pharmaceuticals, Inc. was last trading at $16.41 per share. This represents the most recent stock quote for KalVista Pharmaceuticals, Inc.. Yesterday, KalVista Pharmaceuticals, Inc. closed at $16.40 per share.
-
How To Buy KalVista Pharmaceuticals, Inc. Stock Online?
In order to purchase KalVista Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get KALV Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
KALV
Sector
P/E ratio
--
23.66x
PEG ratio
-0.40x
-0.01x
P/B ratio
48.77x
1.84x
Price / LTM sales
56.89x
1.60x
Growth Metrics
KALV
Sector
Revenue growth
--
4.85%
Earnings growth
-1.45%
11.15%
Revenue (5-year growth)
-100%
6.45%
Earnings forecast
-$1.04
-$0.20
Profitability
KALV
Sector
Profitability FY 2025
-$941K
$3.6M
Return on invested capital
-97.51%
-30.98%
Return on assets
-84.6%
-27.62%
Return on equity
-243.25%
-36.69%
Earnings Date
Last Earnings Date
Nov
10
Next Earnings Date
Mar
24
Estimated Next Earnings Date
Feb
9
Balance Sheet
KALV
Sector
Total cash
$309.2M
$27.2M
Short term investments
$89M
$25.7M
Total assets
$250.8M
$79.9M
Long term debt
$281.2M
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
